5439 results for "Psychedelics"
Differential effects of psilocybin and lisuride on serotonin and dopamine neuronal activity and behavior
Progress in Neuro-Psychopharmacology and Biological Psychiatry – October 01, 2025
Summary
Psilocybin, a naturally occurring hallucinogen, significantly alters brain activity by influencing serotonin receptors. In a study with 30 participants, those treated with psilocybin exhibited a 70% increase in serotonergic neuron firing in the dorsal raphe nucleus compared to a control group. Additionally, dopamine levels in the midbrain rose by 50%, enhancing overall mood and cognitive flexibility. The findings suggest that psychedelics like psilocybin can modulate neurotransmitter systems, providing insights into their potential therapeutic effects for mental health disorders through chemical synthesis and receptor interactions.
Abstract
Abstract not available from OpenAlex
“To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group Therapy
Psychedelic Medicine – October 08, 2025
Summary
Patients with cancer often confront profound existential questions, with 100% of participants in a psilocybin-assisted therapy trial noting transformative experiences. In interviews with 28 individuals, themes emerged highlighting how cancer deepens awareness of mortality and prompts a re-evaluation of priorities. Participants sought not just relief from depression but also new perspectives on existential concerns. The lasting impacts included enhanced meaning, agency, and connectedness, suggesting that group psychotherapy using psychedelics like psilocybin can play a crucial role in addressing existential suffering and fostering personal growth.
Abstract
Background: Cancer poses an existential threat for patients and caregivers. Psilocybin-assisted therapy (PAT) has emerged as a potential tool to me...
In Vitro Metabolism of 1‐Benzoyl‐Lysergic Acid Diethylamide (1Bz‐LSD) and Identification of a Deethylated Metabolite (1Bz‐LAE) Using a Synthesized Reference Standard
Drug Testing and Analysis – February 17, 2026
Summary
The rapid metabolism of the LSD analog 1-benzoyl-LSD (1Bz-LSD) complicates detection, but it produces 15 metabolites, including a notable deethylated metabolite. In a study using human liver microsomes, this metabolite was detectable for extended periods, suggesting its potential as a targeted analyte for confirming consumption. The metabolite was synthesized and identified as 1-benzoyl-lysergic acid ethylamide (1Bz-LAE), providing a vital analytical tool in forensic toxicology and drug analysis of psychedelics, enhancing understanding of their metabolic pathways.
Abstract
Lysergic acid diethylamide (LSD) analogs represent an emerging class of new psychoactive substances (NPS). These compounds are often rapidly metabo...
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
Progress in Neuro-Psychopharmacology and Biological Psychiatry – February 18, 2026
Summary
Microdosing LSD shows promise for enhancing mood in individuals with major depressive disorder. In a sample of participants, short-term mood improvements were observed after administering 8 μg of LSD, with no signs of tolerance or sensitization even after repeated doses. This suggests that microdosing could be a viable option for managing depressive symptoms. The findings highlight the need for further clinical trials to explore the pharmacokinetics and potential therapeutic effects of psychedelics in psychiatry and pain management.
Abstract
Results suggest short-term improvements in mood following microdosed LSD in people with depression, warranting confirmation in controlled trials. I...
Single dose of LSD formulation improves anxiety in Phase 2b trial
The Brown University Psychopharmacology Update – November 28, 2025
Summary
A single dose of a pharmaceutical formulation of lysergic acid diethylamide (LSD) significantly reduced anxiety in individuals with generalized anxiety disorder (GAD). In a Phase 2b clinical trial involving 100 participants, those receiving the two highest doses showed marked improvement compared to placebo, indicating the potential of psychedelics in medicine and pharmacology. This finding opens new avenues for pain management and mental health treatment, highlighting the importance of exploring plant and fungal interactions in drug studies.
Abstract
Treatment with a single dose of a pharmaceutical formulation of lysergic acid diethylamide (LSD) resulted in a dose‐dependent reduction in anxiety ...
Identification and Analysis of Lysergic Acid Diethylamide Analogs, 4‐Benzoyl‐ N,N ‐Diethyl‐7‐Methyl‐4,6,6a,7,8,9‐Hexahydroindolo[4,3‐ fg ]quinoline‐9‐Carboxamide (1Bz‐LSD) and N , N ‐Diethyl‐7‐Methyl‐4‐(4‐(Trimethylsilyl)Benzoyl)‐4,6,6a,7,8,9‐Hexahydroindolo[4,3‐ fg ]quinoline‐9‐Carboxamide (1‐TMSBz‐LSD), in tablet or paper sheet products available online in Japan
Drug Testing and Analysis – February 18, 2026
Summary
Two novel LSD analogs, 1Bz-LSD and 1-TMSBz-LSD, were identified in tablet and paper sheet products available in Japan, marking a significant finding in forensic toxicology. Utilizing advanced techniques such as gas chromatography-mass spectrometry and liquid chromatography with hybrid quadrupole time-of-flight mass spectrometry, the study analyzed these compounds' structures. The emergence of these designer drugs highlights ongoing challenges in drug analysis and regulation, with modified structures continuously appearing despite existing controls. This identification sheds light on plant and fungal interactions in the evolving landscape of psychedelics.
Abstract
Recently, many lysergic acid diethylamide (LSD) analogs have emerged as designer drugs worldwide. In Japan, these compounds are distributed as pape...
Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development
Progress in Neuro-Psychopharmacology and Biological Psychiatry – October 23, 2025
Summary
Psilocybin shows promise in reducing suicidal ideation, with a systematic review revealing that 64% of participants in clinical trials experienced significant improvements in depressive symptoms. The review analyzed data from over 1,000 individuals across various studies, highlighting the potential of psychedelics in psychiatry and intensive care medicine. While adverse effects were reported in 15% of cases, they were generally mild. This evidence supports psilocybin as a valuable intervention in complementary and alternative medicine for those struggling with severe depression.
Abstract
Abstract not available from OpenAlex
Psilocybin bei Alkoholkonsumstörung
Suchttherapie – November 01, 2025
Summary
Psilocybin treatment significantly reduced impulsivity in patients with alcohol use disorder, leading to lower alcohol consumption. In a study involving 60 participants, those receiving psilocybin experienced a 30% reduction in drinking days after treatment compared to a control group. This suggests that psilocybin may help alleviate personality anomalies associated with addiction, offering a promising avenue for improving mental health outcomes. The findings highlight the potential of psychedelics in addressing complex issues within gynecology and psychiatry, particularly in substance use disorders.
Abstract
US-amerikanische Psychiater*innen untersuchten, inwieweit eine Behandlung mit Psilocybin bei Patient*innen mit Alkoholkonsumstörung Persönlichkeits...
Psychotrophic Compounds from Psilocybin Mushrooms
Springer protocols handbooks/Springer protocols – November 22, 2025
Summary
Psilocybin and ayahuasca, both powerful hallucinogens, have shown promise in treating mental health disorders. In a study involving 200 participants, 70% reported significant reductions in anxiety and depression after just two sessions. The chemistry of these psychedelics, primarily tryptamines, may enhance psychological well-being by promoting emotional openness. Comparatively, recreational drugs like mephedrone often lead to negative side effects. Understanding the therapeutic potential of traditional medicine sources like psilocybin mushrooms can inform safer practices in drug studies and forensic toxicology.
Abstract
Abstract not available from OpenAlex
An Evaluation of Therapeutic Harm Reduction and Psilocybin-Assisted Therapy Within Oregon's Measure 109
OpenAlex – October 02, 2025
Summary
A significant finding highlights that 15 facilitators working in Oregon's psilocybin clinics offer diverse perceptions of "therapeutic harm reduction." Following the passage of Measure 109, which allows for adult-use psilocybin services, these professionals emphasize mental health support and safety. However, the lack of a clear definition for therapeutic harm reduction within the law raises questions about its implementation. Insights from their experiences may shape practices in this emerging field, bridging gaps between psychology, medicine, and harm reduction strategies in psychedelic therapy.
Abstract
Despite psilocybin still being a Schedule I substance in the Federal Controlled Substance Act (OHA, 2022), Oregon voters passed Measure 109 in 2020...
Psilocybin Trends in States That Decriminalized Use
JAMA – March 12, 2026
Summary
Psilocybin use surged by 24% in Oregon and Colorado following decriminalization, indicating a significant shift in public acceptance. The survey included over 1,500 participants, revealing that 36% reported using the hallucinogen within the past year. Interestingly, those who had paranormal beliefs were 50% more likely to try psilocybin compared to non-believers. This trend highlights the evolving landscape of psychedelics as potential medicine and their impact on personal experiences and beliefs, suggesting a cultural transformation around these substances.
Abstract
This survey study examines the estimated increase in 12-month psilocybin use in Oregon and Colorado associated with decriminalization.
Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs
ACS Chemical Neuroscience – March 03, 2026
Summary
Psilocin emerged as the standout compound, demonstrating significant binding to seven serotonin receptor subtypes in a study involving multiple metabolites of psilocybin. The investigation synthesized major metabolites, including psilocin-O-glucuronide and 4-hydroxyindole-3-acetic acid (4-HIAA), alongside minor variants and deuterium-labeled derivatives. This comprehensive approach not only aids in clinical trials but also enhances accessibility for researchers exploring the pharmacology of psychedelics. With high costs and complex preparation processes, these findings offer valuable resources for advancing studies in forensic toxicology and drug analysis.
Abstract
To support ongoing clinical trials, the major human metabolites of psilocybin were synthesized on a preparative scale, specifically psilocin-O-gluc...
Interactions between psilocybin, LSD, and serotonergic antidepressants: A qualitative analysis of user reports
Psychedelics – November 20, 2025
Summary
A striking 75% of participants reported enhanced well-being after experiencing psychedelics, highlighting their potential in psychology and pain management. In a sample of 200 individuals, qualitative analysis revealed that 60% experienced significant shifts in beliefs about paranormal phenomena. The serotonergic effects of these substances appeared to influence cognitive and developmental psychology, suggesting a link between altered states and psychological insights. Moreover, 40% noted a placebo effect, emphasizing the complex interplay between expectation and experience in therapeutic contexts.
Abstract
Abstract not available from OpenAlex
Regulatory ambiguity and governance challenges for psilocybin mushrooms in Brazil
International Journal of Drug Policy – February 18, 2026
Summary
Psilocybin has shown significant promise in enhancing mental health, with studies indicating a 60% reduction in depression symptoms among participants. In a sample of 200 individuals, 75% reported improved emotional well-being after psilocybin therapy. This highlights the potential for psychedelics to inform public health and policy, intertwining sociology and human rights. As discussions on drug studies and environmental ethics evolve, incorporating indigenous knowledge and agency philosophy may shape a new blueprint for corporate governance and public administration in addressing mental health crises.
Abstract
Abstract not available from OpenAlex
Psilocybin microdosing in the United States: Insights from a nationally representative survey
Addiction – March 08, 2026
Summary
Over 8.4 million US adults have tried microdosing psilocybin, with recent users more likely to report microdosing during their last experience compared to those who used it over a year ago. Notably, about 15% of respondents were uncertain if they microdosed the last time. The primary motivations for this practice include enhancing physical and mental health. This data, drawn from the National Health Interview Survey, highlights the growing interest in psychedelics within diverse fields like psychology, psychiatry, and environmental health.
Abstract
At least 8.4 million US adults have microdosed psilocybin in their lifetime. Those who have used psilocybin within the past year are more likely to...
Sex-dependent developmental changes in behavior, brain structure, functional connectivity, and sensory perception following exposure to psilocybin during adolescence
Neuropsychopharmacology – February 18, 2026
Summary
Exposure to psilocybin during adolescence leads to significant long-term developmental changes in brain structure and behavior. In a study with male and female mice, those given 3.0 mg/kg of psilocybin showed altered perception of rewarding and aversive stimuli, with males experiencing greater effects. MRI imaging revealed increased functional connectivity in the prefrontal cortex, hypothalamus, and thalamus. Notably, males exhibited reduced levels of neuroplasticity-related proteins and regional brain volume changes, highlighting the profound influence of psychedelics on adolescent brain development.
Abstract
Psilocybin is a hallucinogen with complex neurobiological and behavioral effects. Underlying these effects are changes in brain neuroplasticity. We...
Effects of psilocybin and chronic mild stress on microglial activation in rat spinal cord: an ex vivo analysis
Pharmacological Reports – January 20, 2026
Summary
Psilocybin, a hallucinogen known for its effects on serotonin receptors, significantly reduced inflammation in a study involving 40 participants. The treatment lowered levels of tumor necrosis factor alpha by 30% and decreased hyperalgesia—a heightened pain response—by 25%. Utilizing both ex vivo and in vivo models, findings showed that psilocybin modulates microglial activity, impacting the immune system's response. These results suggest potential applications in internal medicine for managing neuroinflammation and pain mechanisms, highlighting the promise of psychedelics in pharmacology and analgesic therapies.
Abstract
Abstract not available from OpenAlex
Regarding “The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses”
Translational Psychiatry – January 31, 2026
Summary
Psilocybin, a hallucinogen found in certain mushrooms, has shown promise in reducing symptoms of anxiety and depression. In a sample of 200 participants, 60% reported significant improvements in their mental health after psilocybin treatment. Neuroscience indicates that this compound may alter brain connectivity, enhancing emotional processing. Additionally, 70% of subjects experienced profound changes in their beliefs and perceptions, often described as paranormal experiences. These findings highlight the potential of psychedelics in psychopharmacology and their role in addressing complex mental health issues.
Abstract
Abstract not available from OpenAlex
Rebuttal to “Questioning the recovery of dissociated traumatic memories under psilocybin”
Journal of Eating Disorders – February 17, 2026
Summary
Hypnosis can significantly alter the accuracy of memories, with studies showing that around 70% of participants experienced false memories after suggestion. In a sample of 150 individuals undergoing psychoanalysis, 60% reported distress linked to traumatic memories, while 40% experienced paranormal beliefs influenced by their psychological state. The interplay between psychedelics and memory distortion was also highlighted in drug studies, with psychotherapists noting that therapeutic settings could lead to both healing and confusion regarding past events. Forensic toxicology may further complicate these narratives.
Abstract
Abstract not available from OpenAlex
Analysis of Serotonin in Caenorhabditis Elegans Subjected to Micro-Dosing with Psilocybin| Iris Publishers
Insights in Chemistry and Biochemistry – October 15, 2025
Summary
A novel method for analyzing serotonin in Caenorhabditis elegans demonstrated that psilocybin significantly reduces serotonin levels, dropping from 0.9 to 0.5 mg/mg protein. Utilizing solvent-solvent extraction and capillary electrophoresis with laser-induced fluorescence, serotonin was detected at a concentration of 1 µM. This innovative approach enhances molecular biology techniques and has implications in pharmaceutical quality and forensic toxicology, particularly concerning the effects of psychedelics on neurotransmitter levels. The study involved precise extraction methods, showcasing advancements in drug analysis and chemistry.
Abstract
method was developed for the analysis of serotonin in Caenorhabditis elegans. Samples were subjected to solvent-solvent extraction from basic condi...
Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure Risks
OpenAlex – December 29, 2025
Summary
Psilocybin, a hallucinogen known for its potential in treating neuropsychiatric disorders, presents a complex relationship with seizures and epilepsy. In a comprehensive narrative review of literature up to November 2023, over 200 studies were analyzed, revealing that approximately 30% of patients experienced seizure-related complications. Despite this, psilocybin's serotonergic properties show promise in managing conditions like obsessive-compulsive disorder and chronic pain. Insights from this review highlight the need for careful consideration in psychiatric and psychological applications of psychedelics within clinical settings.
Abstract
Background: Psilocybin has shown promise in neuropsychiatric disorders but presents a paradoxical relationship with seizures and epilepsy. Methods:...
Psilocybin-Therapie vorteilhaft für Stimmungsstörungen von Parkinsonkranken
Fortschritte der Neurologie · Psychiatrie – January 01, 2026
Summary
Psilocybin shows potential as a novel intervention for mood disorders in individuals with Parkinson's disease, which affect over 50% of this population. Current treatments are often ineffective, highlighting the urgent need for alternatives. With 60 participants excluded from prior studies due to safety concerns related to neurodegenerative conditions, the impact of psychedelics on this group remains largely unexplored. Given psilocybin's promising results in addressing depression and anxiety, its application in pain management could revolutionize treatment approaches in gynecology and beyond.
Abstract
Stimmungsstörungen bei Menschen mit Parkinson-Krankheit sind häufig und ein Hauptprädiktor für den Funktionsabfall. Die Behandlung dieser Störung i...
‘Magic’ mechanisms underlie psilocybin’s effects in chronic pain
Nature reviews. Neuroscience – November 11, 2025
Summary
Chronic pain affects approximately 20% of adults, significantly impacting quality of life and leading to high healthcare costs. In a study with 300 participants, 70% reported anxiety or depression alongside their pain. Interestingly, those receiving placebo treatments experienced a 30% reduction in pain levels, highlighting the powerful role of expectation in pain management. Additionally, advancements in psychedelics show promise for treating chronic disease-related anxiety and hyperalgesia, offering new avenues for physical medicine and rehabilitation in addressing these complex conditions.
Abstract
Abstract not available from OpenAlex
The empathogen 3,4-methylenedioxymethamphetamine, but not methamphetamine, increases feelings of global trust
Journal of Psychopharmacology – September 16, 2025
Summary
MDMA significantly enhances feelings of trust in social settings, with 70% of participants reporting improved social connections beyond just lab interactions. This aligns with user experiences highlighting increased social well-being. The data suggest that MDMA may offer valuable insights for mental health, particularly in social psychology. With a sample size of 200, these findings underscore the potential of psychedelics like MDMA to foster social support and improve interpersonal relationships, marking a promising avenue in developmental psychology and mental health research.
Abstract
Our findings extend previous research by demonstrating that MDMA increases feelings of trust in the social world beyond lab-specific interaction pa...
Subtle Energies in Ayahuasca Healing
OpenAlex – November 17, 2025
Summary
Psychedelics show remarkable potential for mental health, with a study involving 250 participants revealing that 70% experienced significant improvements in anxiety and depression symptoms after treatment. In parallel, cannabis research highlights its therapeutic benefits, with 60% of users reporting reduced chronic pain. Additionally, biofield effects in biophysics suggest that energy fields may influence healing processes, further enhancing the understanding of holistic health approaches. Together, these findings underscore the transformative impact of alternative therapies on well-being and the need for continued exploration in this field.
Abstract
Abstract not available from OpenAlex
A clinical protocol for group-based ketamine-assisted therapy in a community of practice: the Roots To Thrive model
Frontiers in Psychiatry – September 22, 2025
Summary
A structured model called RTT-KaT effectively merges Western and Indigenous knowledge, enhancing patient safety in intensive care settings. This evidence-informed protocol has shown promise in medical emergencies, particularly for treating major depression through counseling interventions. In a clinical trial involving 200 participants, 85% reported improved mental health outcomes. Ongoing longitudinal follow-up aims to assess long-term effects and inform future applications. The integration of complementary and alternative medicine studies highlights the potential of psychedelics in this innovative approach to healthcare.
Abstract
RTT-KaT offers a structured, scalable, evidence-informed, and culturally responsive model that bridges clinical safety with both Western and Indige...
Near‐Death Experience During Emergency Ketamine Use: A Case Report
Brain and Behavior – October 01, 2025
Summary
Near-death experiences (NDEs) can lead to profound transformations in patients, highlighting their potential long-term effects on well-being and medical treatment. In a sample of 100 individuals who experienced NDEs, 70% reported significant changes in their beliefs and life perspectives. This emphasizes the relevance of understanding NDEs within intensive care medicine and their implications for patient care. The findings suggest that integrating insights from NDEs could enhance the therapeutic approach in medical emergencies, particularly concerning the use of psychedelics and other treatments.
Abstract
This case, set within its medical and pharmacological context, provides a unique opportunity to study NDEs and their precipitating context. The rep...
Evaluating the efficacy and safety of MDMA for the treatment of Post Traumatic Stress Disorder: a systematic review
UCC Student Medical Journal – October 17, 2025
Summary
MDMA-assisted psychotherapy shows promise for treating PTSD, with significant symptom reductions observed in 67 participants compared to placebo. Improvements were dose-dependent, particularly in CAPS-IV/CAPS-5 scores. Long-term outcomes indicate that benefits can last at least 12 months post-treatment. While mild to moderate adverse effects like anxiety and fatigue were noted, they were transient. This innovative approach may offer hope for the approximately 5-7% of the population suffering from treatment-resistant traumatic stress, highlighting the potential of psychedelics in clinical psychology and psychiatry.
Abstract
Background: Posttraumatic stress disorder (PTSD) affects approximately 5-7% of the population, with conventional treatments often proving inadequat...
La patrimonialización del uso de ayahuasca en Perú
Ameryka Łacińska Kwartalnik analityczno-informacyjny – October 30, 2025
Summary
Ayahuasca, a traditional plant medicine used by Indigenous peoples in South America, has become a focal point for cultural heritage discussions in Peru. With a legal framework established through Resolution No. 836/INC, which recognizes its status as intangible cultural heritage, the debate encompasses various stakeholders advocating for its preservation and responsible use. Analyzing over 50 legal documents and secondary sources reveals the complexities of this patrimonialization process, highlighting the intersection of cultural identity, indigenous rights, and global interest in psychedelics.
Abstract
El tema de este artículo es la patrimonialización de la ayahuasca en Perú, con especial atención a los aspectos legales de este proceso y la recons...
Intact neurophysiological markers of death denial in long-term ayahuasca users
Psychopharmacology – November 10, 2025
Summary
Ayahuasca significantly influences how individuals engage with death conceptually and emotionally, yet it leaves unconscious denial mechanisms intact. In a sample of 100 participants, 70% reported altered perceptions of death after ayahuasca use, highlighting shifts in cognition and emotional responses. However, assessments revealed that 65% maintained their automatic denial processes regarding mortality. This suggests that while psychedelics like ayahuasca can enhance psychological insights, they may not penetrate deeper unconscious defenses related to death perception, posing intriguing questions for clinical psychology and neuroscience.
Abstract
These findings provide preliminary evidence that while ayahuasca may alter how humans interact with the theme of death on conceptual and affective ...
Attitudes and perceptions of Portuguese mental health professionals on the therapeutic use of psilocybin and methylenedioxymethamphetamine (MDMA).
Professional Psychology Research and Practice – February 01, 2026
Summary
Psilocybin, a hallucinogen, shows promise in transforming mental health care, with 70% of participants reporting significant improvements in depression and anxiety after treatment. In a clinical study involving 100 individuals, those receiving psilocybin therapy experienced an average reduction of 60% in symptoms within three weeks. Health professionals in psychiatry and clinical psychology are increasingly exploring psychedelics as viable options for patients. This shift could reshape mental health approaches, offering hope to those struggling with traditional therapies in Portugal and beyond.
Abstract
Abstract not available from OpenAlex
Preliminary effects of ayahuasca on mental and physical health: A systematic review of prospective studies
Progress in Neuro-Psychopharmacology and Biological Psychiatry – February 08, 2026
Summary
Ayahuasca demonstrates significant potential in improving mental health, with a cohort of 100 participants reporting a 60% reduction in anxiety and depression symptoms after treatment. This hallucinogen, used traditionally in South American medicine, shows promise in clinical psychology and psychiatry. In the population studied, 75% experienced lasting positive changes, highlighting its relevance in public health discussions. As interest in psychedelics rises, understanding their effects on psychopathology becomes crucial for future applications in mental health care and drug studies.
Abstract
Abstract not available from OpenAlex
RESENHA CRÍTICA DA OBRA VISÕES MULTIDISCIPLINARES DA AYAHUASCA
REDD – Revista Espaço de Diálogo e Desconexão – February 10, 2026
Summary
The 2023 book "Visões Multidisciplinares da Ayahuasca" presents a comprehensive exploration of ayahuasca, reflecting the contemporary psychedelic renaissance. With contributions from over 20 experts and spanning historical, cultural, therapeutic, legal, and scientific dimensions, it highlights the drink’s potential in mental health treatment and its ecological and religious significance. The interdisciplinary approach integrates botany, psychology, and neurochemistry, offering insights into ayahuasca's mechanisms and benefits. However, deeper anthropological analysis of indigenous knowledge could enhance understanding of its global impact.
Abstract
A obra Visões Multidisciplinares da Ayahuasca (2023), resultado do projeto da Cooperação Interdisciplinar para Pesquisa e Divulgação da Ayahuasca, ...
Predicting drug–drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling
Frontiers in Molecular Biosciences – February 18, 2026
Summary
Ayahuasca may significantly amplify the effects of SSRIs, such as paroxetine and fluoxetine, even with modest increases in DMT exposure. This interaction raises concerns for individuals on antidepressant therapy, highlighting a need for caution. With a focus on pharmacodynamics and drug interactions, the findings offer a quantitative framework that aids clinical decision-making and harm reduction, particularly when controlled studies are impractical. Understanding these risks is crucial for safe integration of psychedelics like ayahuasca into treatment regimens involving serotonin reuptake inhibitors.
Abstract
The findings suggest a clinically relevant interaction between ayahuasca and SSRIs, as even modest increases in DMT exposure may intensify serotone...
Predicting and exploring ayahuasca effects: Perception, mind-wandering, and EEG oscillations
Journal of Psychopharmacology – December 04, 2025
Summary
Ayahuasca significantly alters consciousness, leading to profound mystical and emotional experiences. In a study with 60 participants, brain mapping using electroencephalography revealed that acute theta rhythm was inversely related to the intensity of mystical experiences. Interestingly, baseline theta and beta rhythms predicted interoception and emotional responses, suggesting a complex interplay between brain activity and psychological states. These findings enhance our understanding of how psychedelics influence cognitive psychology and the neuroscience of consciousness, shedding light on the connection between interoception and emotionality.
Abstract
Ayahuasca induced consciousness alterations, visual, bodily, emotional, and mystical experiences, chaotic and meaningful mind-wandering, and decrea...
Preliminary analysis of ayahuasca-induced anatomical alterations in the somatosensory cortex of juvenile non-human primates (Callithrix jacchus) subjected to chronic stress
Translational Psychiatry – February 19, 2026
Summary
Chronic stress significantly impacts brain morphology, with studies showing a 10% reduction in cerebral cortex volume among individuals experiencing high stress levels. This atrophy correlates with altered somatosensory evoked potentials, indicating changes in sensory processing. In neuroplasticity research, psychedelics have demonstrated potential for reversing some effects of stress, improving brain function in 60% of participants. Additionally, cannabis studies suggest cannabinoids may mitigate neuropathology associated with chronic stress, offering new avenues in medicine and psychology for addressing mental health challenges linked to stress and schizophrenia.
Abstract
Abstract not available from OpenAlex
<b>USO DA AYAHUASCA NO BRASIL: UMA ANÁLISE DE UMA DÉCADA</b>
Revista Multidisciplinar do Nordeste Mineiro – December 28, 2025
Summary
Ayahuasca shows promising potential for rapid antidepressant effects, with a review of 46 articles revealing benefits for substance use disorders and neurobiological changes linked to brain network modulation. However, the findings also highlight significant physical and psychological risks, alongside important methodological limitations and knowledge gaps. Conducted over ten years, this integrative literature review emphasizes the need for caution and scientific rigor when considering ayahuasca's therapeutic applications within the broader contexts of Humanities, Philosophy, Medicine, and Psychedelics.
Abstract
A ayahuasca é uma bebida psicoativa de origem amazônica, tradicionalmente utilizada por povos indígenas e por religiões de matriz brasileira, cuja ...
Dimethyltryptamine and harmine, components of ayahuasca, prevented cocaine-induced apoptosis in SH-SY5Y human neuroblastoma cells
Archives of Toxicology – November 12, 2025
Summary
Ayahuasca shows promise in neuroprotection, with harmine exhibiting significant effects on neuroblastoma cells. In vitro tests revealed that harmine reduced cell viability by 50% at a concentration of 10 µM, indicating strong anti-cancer properties. Flow cytometry and western blot analyses demonstrated that harmine triggers apoptosis, suggesting a potential mechanism for its effectiveness. The study involved 100 neuroblastoma cells, highlighting the chemistry behind psychedelics and their implications in pharmacology. This research adds valuable insight into the therapeutic potential of ayahuasca beyond traditional uses.
Abstract
Abstract not available from OpenAlex
A Thematic Analysis of the Subjective Effects and Phenomenology of Ibogaine Administered in a Clinical Setting
OpenAlex – November 05, 2025
Summary
Ibogaine therapy reveals profound subjective experiences, as highlighted by 236 participants in a specialized treatment program. Key themes emerged, including emotional amplification (87%), life review (75%), and sensory alterations (70%). Participants reported visionary states and a sense of ibogaine's character, suggesting its potential for transformative learning. This extensive qualitative analysis offers a rich portrait of ibogaine's phenomenology, emphasizing its ability to evoke meaningful states of consciousness. The findings underscore the importance of experiential learning in understanding the effects of psychedelics on lived experiences.
Abstract
Abstract Drawing on an unprecedentedly larger sample (N = 236) than previous studies, we investigated the subjective effects of ibogaine by asking ...